Tychan
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8881 Fletcher Pkwy Ste 103, La Mesa, Cal...Phone Number
(619) 463-7770Website
www.tychan.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Tychan
Tychan, a Singapore-based clinical-stage biotechnology company, is focused on bringing life-saving treatments for emerging infections to those in need through disruptive technologies. In a coordinated effort with regulatory authorities, the company is accelerating the translation from non-clinical studies to clinical trials for emerging pathogens. Founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, whose expertise spans the fields of biologics development and biology of acute viral infections. Temasek Holdings is the founding investor of Tychan.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tychan your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Tychan
Funding: Get notified immidiatlly once Tychan has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Tychan had a recent Job posting/layoffs
Product Launch: Get notified when Tychan launches new products
Earning: See what the market has to say on Tychan recently announced quarterly report
Check if Tychan has recently received funding, and reach out quickly before it becomes old news!
Check out if Tychan is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Tychan, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Tychan as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Tychan is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tychan is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tychan.
Tychan Tech Stack
A closer look at the technologies used by Tychan
See more technologies
Tychan News & Media
Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027
SINGAPORE--(BUSINESS WIRE)--In June 2020, Tychan began its Phase 1 clinical safety trials in humans to evaluate TY027, a monoclonal antibody (mAb) that specifically targets SARS-CoV-2, the virus that causes COVID-19. In October 2020, approval from Health Sciences Authority of Singapore (HSA) was obtained for the Phase 3 clinical trial to begin as part of the progression of the antibody development. The trial will start in Singapore at partner hospitals Singapore General Hospital and National UnNEJM Study Demonstrates Safety and Efficacy of First Novel Monoclonal Antibody Specifically Developed to Treat Yellow Fever
SINGAPORE--(BUSINESS WIRE)--Tychan announced a publication in New England Journal of Medicine (NEJM) that offers a roadmap for research of therapeutics for infectious diseasesTychan to Begin First Clinical Trials for First Novel Monoclonal Antibody Against COVID-19
SINGAPORE--(BUSINESS WIRE)--Tychan, a Singapore-based clinical-stage biotechnology company, is initiating Phase 1 clinical trials to evaluate TY027, the first novel monoclonal antibody (mAb) that specifically targets SARS-CoV-2, the virus that causes COVID-19. Through the use of the company’s proprietary technology and rapid response techniques, the trial is expected to take only about six weeks. TY027 showed full clearance of the virus in laboratory studies and demonstrated safety in preclinicWuXi Biologics Congratulates Tychan on the World's First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
SHANGHAI, Nov. 18, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today congratulates its partner Tychan on successful...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Tychan
Sign Up For FreeTo access detailed company insights
Tychan, a Singapore-based clinical-stage biotechnology company, is focused on bringing life-saving treatments for emerging infections to those in need through disruptive technologies. In a coordinated effort with regulatory authorities, the company is accelerating the translation from non-clinical studies to clinical trials for emerging pathogens.... Read More
